Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.
Isermann T, Schneider KL, Wegwitz F, De Oliveira T, Conradi LC, Volk V, Feuerhake F, Papke B, Stintzing S, Mundt B, Kühnel F, Moll UM, Schulz-Heddergott R. Isermann T, et al. Among authors: stintzing s. bioRxiv [Preprint]. 2024 Feb 26:2024.02.22.581507. doi: 10.1101/2024.02.22.581507. bioRxiv. 2024. PMID: 38464125 Free PMC article. Preprint.
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
Boukovala M, Modest DP, Ricard I, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Peveling Genannt Reddemann C, Graeven U, Schuch G, Schwaner I, Heinrich K, Neumann J, Jung A, Held S, Stintzing S, Heinemann V, Michl M. Boukovala M, et al. Among authors: stintzing s. ESMO Open. 2024 May;9(5):103374. doi: 10.1016/j.esmoop.2024.103374. Epub 2024 May 13. ESMO Open. 2024. PMID: 38744100 Free PMC article. Clinical Trial.
Management of colorectal cancer.
Stintzing S. Stintzing S. F1000Prime Rep. 2014 Nov 4;6:108. doi: 10.12703/P6-108. eCollection 2014. F1000Prime Rep. 2014. PMID: 25580262 Free PMC article. Review.
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
Vangala D, Ladigan S, Liffers ST, Noseir S, Maghnouj A, Götze TM, Verdoodt B, Klein-Scory S, Godfrey L, Zowada MK, Huerta M, Edelstein DL, de Villarreal JM, Marqués M, Kumbrink J, Jung A, Schiergens T, Werner J, Heinemann V, Stintzing S, Lindoerfer D, Mansmann U, Pohl M, Teschendorf C, Bernhardt C, Wolters H, Stern J, Usta S, Viebahn R, Admard J, Casadei N, Fröhling S, Ball CR, Siveke JT, Glimm H, Tannapfel A, Schmiegel W, Hahn SA. Vangala D, et al. Among authors: stintzing s. Genome Med. 2021 Jul 16;13(1):116. doi: 10.1186/s13073-021-00926-7. Genome Med. 2021. PMID: 34271981 Free PMC article.
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
Kawazoe A, Xu RH, García-Alfonso P, Passhak M, Teng HW, Shergill A, Gumus M, Qvortrup C, Stintzing S, Towns K, Kim TW, Shiu KK, Cundom J, Ananda S, Lebedinets A, Fu R, Jain R, Adelberg D, Heinemann V, Yoshino T, Elez E; LEAP-017 Investigators. Kawazoe A, et al. Among authors: stintzing s. J Clin Oncol. 2024 Jun 4:JCO2302736. doi: 10.1200/JCO.23.02736. Online ahead of print. J Clin Oncol. 2024. PMID: 38833658
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).
Heinrich K, Heinemann V, Stintzing S, Müller L, Ettrich TJ, Büchner-Steudel P, Geißler M, Trojan J, Moosmann N, Folprecht G, Schmidt J, Kanzler S, Kullmann F, Moulin JC, Werner J, Angele MK, Probst V, Held S, Schulz C, Boukovala M. Heinrich K, et al. Among authors: stintzing s. Oncol Res Treat. 2024;47(6):251-261. doi: 10.1159/000538143. Epub 2024 Apr 2. Oncol Res Treat. 2024. PMID: 38565089 Clinical Trial.
Cachexia-Affected Survival Based on Inflammatory Parameters Compared to Complex Conventional Nutritional Assessments in Patients with Pancreatic Cancer and Other Gastrointestinal Tumors-The CONKO 020 Investigation.
Meyer-Knees JW, Falkenthal J, Geisel D, Neumann CCM, Hilfenhaus G, Stephan LU, Schöning W, Malinka T, Pratschke J, Stintzing S, Pelzer U. Meyer-Knees JW, et al. Among authors: stintzing s. Cancers (Basel). 2024 Mar 18;16(6):1194. doi: 10.3390/cancers16061194. Cancers (Basel). 2024. PMID: 38539528 Free PMC article.
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
Yoshino T, Hooda N, Younan D, Muro K, Shitara K, Heinemann V, O'neil BH, Herrero FR, Peeters M, Soeda J, Suh M, Reichert H, Mezzi K, Fryzek J, Chia V, Rehn M, Stintzing S. Yoshino T, et al. Among authors: stintzing s. Eur J Cancer. 2024 May;202:113975. doi: 10.1016/j.ejca.2024.113975. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38442645 Review.
VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge.
Kreutzinger V, Pankow A, Boyadzhieva Z, Schneider U, Ziegeler K, Stephan LU, Kübke JC, Schröder S, Oberender C, le Coutre P, Stintzing S, Jelas I. Kreutzinger V, et al. Among authors: stintzing s. J Clin Med. 2024 Feb 12;13(4):1049. doi: 10.3390/jcm13041049. J Clin Med. 2024. PMID: 38398362 Free PMC article.
235 results